code,description
ARR,Array LOH
B14,Mutatie analyse BRCA1 gen
B15,Mutatie analyse BRCA2 gen
B16,MLPA analyse BRCA1
B17,aantonen/uitsluiten in familie bekende mutatie in BRCA1/2
B21,MLPA analyse BRCA2
B22,Mutatie analyse MYO5B gen
B23,Mutatie analyse CHEK2 1100delC
C,OLA analyse
C3,Mutatie analyse CFTR gen
C31,MLPA analyse CFTR
C37,ARMS analyse
C38,OLA analyse en bepaling T-stretch intron 8
C4,bekende mutatie aantonen dan wel uitsluiten
CDKL5,MLPA analyse CDKL5
CF01,analyse CF Elucigene
CF02,analyse CF Elucigene + bepaling T stretch intron 8
CH1,Mutatie analyse TFAP2B gen
CHCK,
CNV01,CNV analyse NGS
CV1,BM CNV analyse NGS ONCO
CV14,CNV + LOH detectie MDS
DC1,Mutatie analyse LMNA gen
DC11,Mutatie analyse DES gen
DC12,Mutatie analyse DSC2 gen
DC13,Mutatie analyse DSG2 gen
DC15,Mutatie analyse PLN gen
DC16,Mutatie analyse MYBPC3 gen
DC17,Mutatie analyse JUP gen
DC18,Mutatie analyse DSP gen
DC2,bekende mutatie aantonen dan wel uitsluiten
DC21,MLPA analyse ACM-PKP2 (DSG2/DSC2/PKP2/DSP/RYR2/JUP)
DC6,Mutatie analyse MYH7 gen
DC8,Mutatie analyse PKP2 gen
DC9,MLPA analyse LMNA
DI1,Verwerken genomisch materiaal
DI11,Mutatie analyse NOTCH 1 gen
DI28,Mutatie analyse BMPR2 gen
DI32,MLPA analyse BMPR2
DI4,in de familie bekende mutatie aantonen/uitsluiten
DI44,Primerdesign en bekende mutatie aantonen/uitsluiten
E01,Mutatie analyse KRT5 gen
E03,Mutatie analyse LAMB3 gen
E08,Mutatie analyse COL17A1 gen
E8,Mutatie analyse KRT14 gen
EA1,Mutatie analyse KCNA1 gen
F01,PCR analyse FMR-1 gen
F3,Mutatie analyse PCSK9 gen
FA1,Mutatie analyse TTR gen
FA4,Mutatie analyse FGA gen
FH1,Mutatie analyse LDLR gen
FH2,Mutatie analyse APOB gen
FH4,MLPA analyse LDLR
FIAR,Analyse CNV data gefilterd op aangevraagd panel
GO1,Mutatie analyse KIAA1279 gen
GS4,Mutatie analyse G6PT1 gen
GS5,Mutatie analyse AGL gen
GS6,Mutatie analyse G6PC gen
H01,MSI onderzoek
H05,Mutatie analyse MSH6 gen
H51,Mutatie analyse MSH2 gen
H52,Mutatie analyse MLH1 gen
H54,Mutatie analyse MUTYH gen
H56,MLH1 hypermethylatie analyse
H59,Mutatie analyse PMS2 gen
H63,MLPA analyse MLH1/MSH2/EPCAM
H65,MLPA analyse MSH6
H66,MLPA analyse PMS2
H67,Mutatie analyse MLH1 op DNA uit P.A. materiaal
H71,Mutatie analyse PMS2 mbv Long Range pcr exon 11 tm 15
H72,analyse MSH2 inversie
HE1,Mutatie analyse ED1 gen
HE12,Mutatie analyse WNT10A gen
HE6,Mutatie analyse EDAR gen
HE7,MLPA analyse EDA; EDAR; EDARADD; WNT10A
HE9,Mutatie analyse EDARADD gen
HR1,Mutatie analyse PHEX gen
HR2,Mutatie analyse FGF23 gen
HR3,MLPA analyse PHEX/FGF23
HS01,Mutatie analyse RET gen
HS03,bekende mutatie aantonen danwel uitsluiten
HS04,Mutatie analyse EDNRB gen
HS29,Mutatie analyse EDN3 gen
HS30,Mutatie analyse SOX10 gen
HS31,Mutatie analyse NODAL gen
HS32,Mutatie analyse PHOX2B gen
HS33,MLPA analyse PHOX2B/SOX10/EDNRB
I01,Deletie analyse van het NEMO gen
I04,x-inaktivatie AR locus
I06,Mutatie analyse NEMO gen
L1,Mutatie analyse L1CAM gen
LF1,Mutatie analyse TP53 gen
LF4,MLPA analyse TP53
LV2,Mutatie analyse GDF1 gen
NGS,targeted NGS Cardio; exclusief PSEN 1/2
NGS1,Analyse NGS CARDIO
NGS10,Bevestigen gevonden mutatie
NGS2,losse amplicons NGS
NGS3,identificatie/bevestiging NGS
NGS4,targeted NGS ONCO; Klasse 1 + 2 + 3
NGS5,targeted NGS ONCO; Klasse 1 + 2
NGS6,targeted NGS ONCO; Klasse 1
NGS9,analyse NGS ONCO; Klasse 3
NX01,analyse NGS Dystonie
NX02,analyse NGS EPI; subpanel 1
NX03,analyse NGS EPI; subpanel 2
NX04,analyse NGS EPI; subpanel 3
NX05,analyse NGS EPI; subpanel 4
NX06,analyse NGS EPI; subpanel 5
NX07,analyse NGS EPI; subpanel 6
NX08,analyse NGS EPI; subpanel 7
NX09,analyse NGS EPI; subpanel 8
NX10,analyse NGS EPI; subpanel 9
NX100,Analyse Exoom; DYST
NX101,Analyse Exoom; DER Overig huid
NX102,Analyse Exoom; DER Epidermolysis Bullosa
NX103,Analyse Exoom; DER Ectodermale Dysplasie
NX104,Analyse Exoom; DER Ectodermale Dysplasie exclusief AXIN2
NX105,Analyse Exoom; FH
NX106,Analyse ExoomINH; o.b.v. HPO termen
NX107,Analyse Exoom; o.b.v. losse genen / regios
NX108,Analyse ExoomINH; o.b.v. HPO + losse genen / regios
NX109,Analyse Exoom; o.b.v. los gen (dragerschap)
NX11,analyse NGS EPI; subpanel 2 en 9
NX110,Analyse Exoom; genpanel 5GPM
NX111,Analyse Exoom; Amyloïdose
NX112,analyse NGS EPI; totaal
NX113,Analyse NGS ONCO; Borstkanker
NX114,Analyse Exoom; NEURO Spastische paraplegie
NX116,Analyse Exoom; CHM Heterotaxie
NX117,Analyse Exoom; CHM Congenitale afwijkingen
NX118,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX119,Analyse NGS ONCO; Borstkanker en LF
NX12,analyse NGS EPI; subpanel 1
NX120,Analyse Exoom; HVZ panel PAH
NX121,Analyse NGS Preconceptie
NX122,Analyse Exoom; PID Autoinflammatoir
NX123,Analyse Exoom; PID  HLH/Immuundisregulatie
NX124,Analyse Exoom; PID ALPS/Autoimmuniteit
NX125,Analyse Exoom; PID (S)CID
NX126,Analyse Exoom; PID  B cel pathologie
NX127,Analyse Exoom; PID HIES syndromen
NX128,Analyse Exoom; PID CMC
NX129,Analyse Exoom; PID totaal
NX13,analyse NGS EPI; subpanel 2
NX130,Analyse Exoom; NEURO Ataxie early onset
NX131,Analyse Exoom; NEURO Ataxie Volwassenen
NX132,Analyse Exoom; NEURO PCH
NX133,Analyse Exoom; DER Epidermolysis Bullosa
NX134,Analyse Exoom; DER Huidfragiliteit overig
NX135,Analyse Exoom; DER Ectodermale Dysplasie
NX137,Analyse Exoom; EPI Benigne familiaire neonatale/infantiele c
NX138,Analyse Exoom; EPI (Early Infantile) Epileptische Enc
NX139,Analyse Exoom; EPI Focale epilepsie
NX14,analyse NGS EPI; subpanel 3
NX140,Analyse Exoom; EPI Koortsgerelateerde convulsies
NX141,Analyse Exoom; EPI Progressieve myoclone epilepsie
NX143,Analyse Exoom; EPI Idiopathische gegeneraliseerde epilepsie
NX144,Analyse Exoom; EPI Epilepsie in combinatie met paroxysmale a
NX145,Analyse Exoom; EPI Syndromen met epilepsie en verst
NX146,Analyse Exoom; EPI Combi van GP Early Inf en syndr
NX147,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX148,Analyse Exoom; FOSFA Hyper-/ en Hypofosfatemie
NX149,Analyse Exoom; Dystonie
NX15,analyse NGS EPI; subpanel 4
NX150,Analyse Exoom; Myoclonus kind
NX151,Analyse Exoom; Myoclonus volwassenen
NX152,Analyse Exoom; NEURO Ataxie volw en Spastische paraplegie
NX153,Analyse NGS CARDIO
NX154,Analyse ExoomINH; open exoom
NX155,Analyse Exoom; DER ED
NX156,Analyse Exoom; DER ED syndromaal
NX157,Analyse Exoom; OA
NX158,Analyse Exoom; genpanel 5GPM
NX160,Analyse Exoom; CHM Congenitale afwijkingen
NX161,Analyse Exoom; KinderDCM
NX162,Analyse Exoom; Prenatale 5GPM
NX163,Analyse ExoomINH; diverse analyses
NX164,Analyse Exoom; HAE Angio-oedeem
NX165,Analyse Exoom; CHM Congenitale afwijkingen
NX166,Analyse Exoom; CHM Heterotaxie
NX167,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX168,Analyse Exoom; Dystonie
NX169,Analyse Exoom; EPI (Early Infantile) Epileptische Enc
NX17,analyse NGS EPI; subpanel 6
NX170,Analyse Exoom; EPI Syndromen met epilepsie en verst
NX171,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX172,Analyse Exoom; EPI Koortsgerelateerde convulsies
NX174,Analyse Exoom; HVZ Aritmie
NX178,Analyse Exoom; HVZ Dyslipidemie (totaal)
NX179,Analyse Exoom; HVZ Hyperalfalipoproteinemie
NX18,analyse NGS EPI; subpanel 7
NX180,Analyse Exoom; HVZ Hypertriglyceridemie
NX182,Analyse Exoom; HVZ LQT
NX183,Analyse Exoom; HVZ Statine resistentie fenotype
NX184,Analyse Exoom; HVZ Hypoalfalipoproteinemie
NX185,Analyse Exoom; LEVER Cholestase
NX187,Analyse Exoom; NEURO Ataxie Volwassenen
NX188,Analyse Exoom; NEURO PCH
NX189,Analyse Exoom; NEURO Spastische paraplegie
NX190,Analyse Exoom; PID (totaal)
NX193,Analyse Exoom; OA
NX194,Analyse Exoom; HVZ Hypercholesterolemie
NX195,Analyse NGS Preconceptie; losse genen
NX196,Analyse Exoom; HVZ Cardiomyopathie
NX197,Analyse Exoom; META Stofwisseling
NX198,Analyse Exoom; genpanel 5GPM
NX199,Analyse Exoom; HVZ Cardiomyopathie
NX20,analyse NGS EPI; subpanel 9
NX200,Analyse Exoom; Noonan syndroom
NX201,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX202,Analyse Exoom; DER ED
NX203,Analyse Exoom; Dystonie
NX204,Analyse Exoom; EPI Syndromen met epilepsie en verstandelijke
NX205,Analyse Exoom; EPI (Early Infantile) Epileptische Encephalop
NX206,Analyse Exoom; EPI Koortsgerelateerde convulsies
NX207,Analyse Exoom; EPI Idiopathische gegeneraliseerde epilepsie
NX208,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX209,Analyse Exoom; NEURO Ataxie Early onset
NX210,Analyse Exoom; NEURO Ataxie Volwassenen
NX211,Analyse Exoom; NEURO Ataxie Volwassenen en Spastische parapl
NX212,Analyse Exoom; panel OA
NX213,Analyse Exoom; PID (totaal)
NX214,Analyse Exoom; KinderDCM
NX215,Analyse Exoom; EPI Combi van GP Early Inf en syndr
NX216,"Analyse Exoom, Prenatale 5GPM"
NX217,Analyse NGS ONCO; losse genen
NX218,Analyse Exoom; genpanel 5GPM
NX219,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX22,analyse NGS DER; subpanel EB
NX220,Analyse Exoom; MDL Cholestase Acuut Leverfalen
NX221,Analyse Exoom; FOSFA Hyper-/ en Hypofosfatemie
NX222,Analyse Exoom; DER Ichthyosis totaal
NX223,Analyse Exoom; NEURO Joubert like
NX224,Analyse Exoom; KinderDCM
NX225,Analyse ExoomINH; Mitochondriëele aandoeningen
NX226,Analyse Exoom; Noonan syndroom
NX227,Analyse Exoom; panel OA
NX228,Analyse Exoom; DER Palmoplantaire Keratoderma
NX229,Analyse Exoom; PID (totaal)
NX23,analyse NGS DER; subpanel ED
NX230,Analyse Exoom; FERTI Prematuur Ovarieel Falen (POF)
NX231,Analyse Exoom; NEURO PCH
NX232,Analyse Exoom; MDL Very Early Onset Inflammatory Bowel Dise
NX233,Analyse Exoom; DER Ichthyosis - geïsoleerd
NX234,DER Ichtyosis syndromaal
NX235,"Analyse Exoom, Prenatale 5GPM"
NX236,Analyse Exoom; CHM Congenitale afwijkingen
NX237,Analyse Exoom; CHM Heterotaxie
NX238,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX239,Analyse NGS ONCO; Borstkanker
NX24,analyse NGS DER; subpanel ED exclusief AXIN2
NX240,Analyse NGS ONCO; Borstkanker en LF
NX241,Analyse NGS ONCO; Darmkanker
NX242,Analyse NGS ONCO; Darmpoliepen
NX243,Analyse NGS ONCO; Eierstokkanker
NX244,Analyse NGS ONCO; Endocrinologie-(bij)schildklierkanker
NX245,Analyse NGS ONCO; Endocrinologie-feochromocytomen
NX246,Analyse NGS ONCO; Endocrinologie-NET
NX247,Analyse NGS ONCO; Huidkanker
NX249,Analyse NGS ONCO; Kinderonco-meningeoma/schwannoma
NX250,Analyse NGS ONCO; Kinderonco-neuroblastoom
NX251,Analyse NGS ONCO; Kinderonco-nierkanker aanvullend
NX252,Analyse NGS ONCO; Leukemie/Lymfoom
NX253,Analyse NGS ONCO; Li Fraumeni syndroom
NX254,Analyse NGS ONCO; Maagkanker
NX255,Analyse NGS ONCO; Nierkanker
NX256,Analyse NGS ONCO; Niet-endocriene alvleesklierkanker
NX257,Analyse NGS ONCO; Prostaatkanker
NX258,Analyse NGS ONCO; Retinoblastoom
NX260,"Analyse Exoom, Prenatale 5GPM"
NX261,Analyse Exoom; genpanel 5GPM
NX262,Analyse Exoom; PID Autoinflammatoir
NX263,Analyse Exoom; PID (totaal)
NX264,Analyse Exoom; NEURO Ataxie Early onset
NX265,Analyse Exoom; KinderDCM
NX266,Analyse Exoom; Noonan syndroom
NX267,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX268,Analyse Exoom; MDL Pancreatitis
NX269,Analyse Exoom; MDL Very Early Onset Inflammatory Bowel Dise
NX27,analyse NGS; subpanel OA
NX270,"Analyse Exoom, Prenatale 5GPM"
NX271,Analyse Exoom; genpanel 5GPM
NX272,Analyse Exoom; PCD Primaire Ciliaire Dyskinesie (PCD)
NX273,Analyse Exoom; panel OA
NX274,Analyse NGS ONCO; Endocrinologie-(bij)schildklierkanker
NX275,Analyse Exoom; LEU Leukemie - Lymfoom
NX276,Analyse Exoom; CHM Congenitale afwijkingen
NX277,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX279,Analyse Exoom; genpanel 5GPM
NX28,analyse 5gpm
NX280,Specifieke vraagstelling ONCO
NX283,Analyse Exoom; 5GPM Prenatale 5GPM
NX284,Analyse Exoom; 5GPM genpanel 5GPM
NX285,Analyse Exoom; 5GPM Prenatale 5GPM rekening houdend met non
NX286,Analyse Exoom; 5GPM genpanel 5GPM rekening houdend met non p
NX287,Analyse Exoom; 5GPM genpanel 5GPM  (i.g.v. incompleet trio)
NX288,Analyse Exoom; DCM KinderDCM
NX289,Analyse Exoom; CHM Congenitale afwijkingen
NX29,analyse NGS ONCO; borst/ei basis
NX290,Analyse Exoom; CHM Heterotaxie
NX291,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX292,Analyse Exoom; HVZ Aritmie
NX294,Analyse Exoom; HVZ Pulmonale arteriële hypertensie
NX295,Analyse Exoom; HVZ Dyslipidemie (totaal)
NX296,Analyse Exoom; FERTI Niet Obstructieve Azoospermie (NOA)
NX297,Analyse Exoom; FERTI Congenitale Bilaterale Agenesie Vas Def
NX298,Analyse Exoom; NEURO Dementie
NX299,Analyse Exoom; NEURO Ataxie Volwassenen
NX30,analyse NGS ONCO; borst/ei aanvullend
NX301,Analyse Exoom; DYST Dystonie
NX302,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX303,Analyse Exoom; EPI Benigne fam neo/infan convulsies
NX304,EPI Necrotiserende encefalopathie
NX305,Analyse Exoom; EPI Koortsgerelateerde convulsies
NX306,Analyse Exoom; FOSFA Hyper-/ en Hypofosfatemie
NX307,Analyse Exoom; OA Ontwikkelingsachterstand en/of aangeboren
NX308,Analyse Exoom; MDL Very early onset inflammatory bowel disea
NX309,Analyse Exoom; PID Autoinflammatoir
NX31,analyse NGS ONCO; borst/ei/maag/darm
NX310,Analyse Exoom; PID B cel pathologie
NX311,Analyse Exoom; PID HIES syndromen
NX312,Analyse Exoom; PID HLH/Immuundisregulatie
NX313,Analyse Exoom; PID (Severe) combined immunodeficiency ((S)CI
NX314,Analyse Exoom; PID (totaal)
NX315,Analyse Exoom; META Stofwisseling
NX317,Analyse Exoom; MDL Pancreatitis
NX318,Analyse Targeted; GROEI Kleine lengte
NX319,Analyse Exoom; LONG Interstitiële longziekten
NX32,analyse NGS ONCO; maag/darm basis
NX320,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX321,Analyse Exoom; HVZ Cardiomyopathie
NX322,Analyse Exoom; HVZ Aritmie
NX323,Analyse Exoom; NEURO Ataxie Early onset
NX324,Analyse Exoom; NEURO Dementie
NX325,Analyse Exoom; HVZ LQT
NX326,Analyse Exoom; 5GPM genpanel 5GPM rekening houdend met non p
NX327,Analyse Exoom; 5GPM genpanel 5GPM
NX328,Analyse Exoom; CHM Congenitale afwijkingen
NX329,Analyse Exoom; DYST Dystonie
NX33,analyse NGS ONCO; maag/darm aanvullend
NX330,Analyse Exoom; DER ED
NX331,Analyse Exoom; OA Ontwikkelingsachterstand en/of aangeboren
NX332,Analyse Exoom; CHM Heterotaxie
NX333,Analyse Exoom; DCM KinderDCM
NX334,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX335,Analyse Exoom; META Stofwisseling
NX336,Analyse Exoom; MYO Myoclonus kind
NX337,Analyse Exoom; NOON Noonan syndroom
NX338,Analyse Exoom; FERTI Prematuur Ovarieel Falen (POF)
NX339,Analyse Exoom; HVZ Pulmonale arteriële hypertensie en Noonan
NX34,analyse NGS ONCO; pancreas
NX340,Analyse Exoom; HVZ Pulmonale arteriële hypertensie
NX341,Analyse Exoom; NEURO Spastische paraplegie
NX342,Analyse Exoom; NEURO Ataxie Volw en Spastische paraplegie
NX343,Analyse Exoom; 5GPM genpanel 5GPM  (i.g.v. incompleet trio)
NX344,Analyse Exoom; 5GPM Prenatale 5GPM
NX345,Analyse Exoom; 5GPM Prenatale 5GPM rekening houdend met non
NX346,Analyse Exoom; MYO Myoclonus volwassenen
NX347,Analyse Targeted; Losse genen
NX348,Analyse Targeted; Borstkanker
NX349,Analyse Targeted; Borstkanker en LF
NX35,analyse NGS ONCO; endocrien
NX350,Analyse Targeted; Darmkanker
NX351,Analyse Targeted; Darmpoliepen
NX352,Analyse Targeted; Eierstokkanker
NX353,Analyse Targeted; Endocrinologie-(bij)schildklierkanker
NX354,Analyse Targeted; Endocrinologie-feochromocytomen
NX355,Analyse Targeted; Endocrinologie-NET
NX357,Analyse Targeted; Huidkanker
NX359,Analyse Targeted; Kinderonco-meningeoma/schwannoma
NX36,analyse NGS ONCO; nier
NX363,Analyse Targeted; Li Fraumeni syndroom
NX364,Analyse Targeted; Longkanker
NX365,Analyse Targeted; Maagkanker
NX366,Analyse Targeted; Nierkanker
NX367,Analyse Targeted; Niet-endocriene alvleesklierkanker
NX368,Analyse Targeted; Prostaatkanker
NX369,Analyse Targeted; Retinoblastoom
NX37,analyse NGS ONCO; huid
NX371,Analyse Targeted; AGL
NX372,Analyse Targeted; G6PC
NX374,Analyse Targeted; EDA
NX375,Analyse Targeted; RET
NX379,Analyse Targeted; PHOX2B
NX38,analyse NGS ONCO; kind/neuro
NX383,Analyse Targeted; L1CAM
NX384,Analyse Targeted; SHOX
NX385,Analyse Targeted; IGHMBP2
NX386,Analyse Targeted; COL2A1
NX387,Analyse Targeted; CFTR
NX388,Analyse Exoom; DCM KinderDCM (i.g.v. incompleet trio)
NX389,"Analyse Exoom; META Stofwisseling (i.g.v. incompleet trio, a"
NX39,analyse NGS ONCO; leukemie/lymfoom
NX390,Analyse ExoomINH; Mitochondriëele aandoeningen (igv incompl
NX391,"Analyse Exoom; OA Ontw achterstand (i.g.v. incompleet trio,"
NX392,Analyse Exoom; PID Autoinflammatoir
NX393,Analyse Exoom; PID (totaal)
NX396,Analyse Exoom; DER Ichthyosis totaal
NX397,Analyse Exoom; DER Ichthyosis - geïsoleerd
NX398,Analyse Exoom; DER Ichtyosis syndromaal
NX399,Analyse Exoom; DER Palmoplantaire Keratoderma
NX40,analyse NGS ONCO; prostaat
NX400,Analyse Exoom; DER Epidermolysis Bullosa
NX401,Analyse Exoom; DER ED
NX402,Analyse Exoom; DER Ectodermale Dysplasie syndromaal
NX403,Analyse Exoom; HAE Angio-oedeem
NX404,Analyse ExoomINH; DCM KinderDCM
NX405,Analyse ExoomINH; DCM KinderDCM (igv incompleet trio)
NX406,Analyse Exoom; CHM Congenitale afwijkingen
NX407,Analyse Exoom; CHM Heterotaxie
NX408,Analyse Exoom; CHM Linkszijdige hartafwijkingen
NX409,Analyse Exoom; PID CMC
NX410,Analyse Exoom; PID (Severe) combined immunodeficiency ((S)CI
NX411,"Analyse Exoom; PID B cel pathologie "
NX412,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX413,Analyse Exoom; NEURO Dementie
NX414,Analyse Exoom; MDL Very early onset inflammatory bowel disea
NX415,Analyse ExoomINH; OA Ontwikkelingsachterstand en/of aangebor
NX416,Analyse ExoomINH; OA Ontw achterstand (igv incompleet trio
NX417,Analyse Targeted; Prostaatkanker
NX418,Analyse Exoom; MDL Pancreatitis
NX419,Analyse Exoom; NEURO Spastische paraplegie
NX420,Analyse Exoom; NEURO Ataxie Volw en Spastische paraplegie
NX421,Analyse ExoomINH; META Stofwisseling
NX422,"Analyse ExoomINH; META Stofwisseling (igv incompl trio, a"
NX425,Analyse ExoomINH; 5GPM genpanel 5GPM
NX426,Analyse ExoomINH; 5GPM genpanel 5GPM (igv incompl. trio)
NX427,Analyse ExoomINH; 5GPM genpanel 5GPM igv nonpenetrantie
NX428,Analyse ExoomINH; 5GPM Prenatale 5GPM
NX429,Analyse ExoomINH; 5GPM Prenatale 5GPM igv nonpen
NX43,analyse NGS ONCO; borst/ei aanvullend
NX430,Analyse Exoom; NOON Noonan syndroom
NX431,Analyse Exoom; HVZ Pulmonale arteriële hypertensie en Noonan syndroom
NX432,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX433,Analyse Exoom; MDL Cholestase Acuut Leverfalen
NX434,Analyse Exoom; DER Chronische Jeuk-volledig
NX435,Analyse Targeted; Borstkanker en PTEN
NX436,Analyse Targeted; Borst- en eierstokkanker
NX437,Analyse Targeted; Darmkanker en -poliepen
NX439,Analyse Exoom; DER Chronische Jeuk-basis
NX44,analyse NGS ONCO; borst/ei/maag/darm
NX447,Analyse Targeted v2; EDA
NX448,Analyse Targeted v2; RET
NX46,analyse NGS ONCO; maag/darm aanvullend
NX460,Analyse Targeted v2; CFTR
NX461,Analyse Targeted v2; GROEI Kleine lengte
NX462,Analyse Targeted v2; Losse genen
NX463,Analyse Targeted v2; Borstkanker
NX464,Analyse Targeted v2; Borstkanker en LF
NX465,Analyse Targeted v2; Darmkanker
NX466,Analyse Targeted v2; Darmpoliepen
NX467,Analyse Targeted v2; Eierstokkanker
NX468,Analyse Targeted; Eierstokkanker
NX471,Analyse Targeted v2; Endocrinologie-feochromocytomen
NX472,Analyse Targeted v2; Endocrinologie-NET
NX474,Analyse Targeted v2; Huidkanker
NX484,Analyse Targeted v2; Niet-endocriene alvleesklierkanker
NX485,Analyse Targeted v2; Prostaatkanker
NX487,Analyse Exoom; LONG Interstitiële longziekten
NX488,Analyse ExoomINH; OA Ontwikkelingsachterstand en/of aangebo
NX489,"Analyse ExoomINH; OA Ontw achterstand (igv incompl. trio,etc"
NX490,Analyse Exoom; NEURO Ataxie Volwassenen
NX491,Analyse Exoom; NEURO Ataxie Volw en Spastische paraplegie
NX492,Analyse Exoom; NEURO Ataxie Early onset
NX493,Analyse Exoom; HVZ Cardiomyopathie en Noonan syndroom
NX494,Analyse Exoom; HVZ Cardiomyopathie
NX495,Analyse ExoomINH; DCM KinderDCM
NX496,Analyse Exoom; DCM KinderDCM (i.g.v. incompleet trio)
NX497,Analyse Exoom; HVZ LQT
NX498,Analyse Exoom; FERTI Niet Obstructieve Azoospermie (NOA)
NX499,Analyse ExoomINH; 5GPM genpanel 5GPM
NX500,Analyse ExoomINH; 5GPM genpanel 5GPM (igv incompl. trio)
NX501,Analyse ExoomINH; 5GPM genpanel 5GPM igv nonpenetrantie
NX502,Analyse ExoomINH; 5GPM Prenatale 5GPM
NX503,Analyse ExoomINH; 5GPM Prenatale 5GPM igv nonpenetrantie
NX504,Analyse Exoom; DER ED syndromaal
NX505,Analyse Exoom; DYST Dystonie
NX506,Analyse Exoom; MYO Myoclonus kind
NX507,Analyse Exoom; MYO Myoclonus volwassenen
NX508,Analyse Exoom; EPI Volledig Epilepsie Genpanel
NX510,Analyse Targeted v2; Borst- en eierstokkanker
NX511,Analyse Targeted v2; Darmkanker en –poliepen
NX512,Analyse Exoom; PCS Preconceptie (i.g.v. medische indicatie)
NX55,analyse klinisch exoom
NX56,analyse NGS Cardio; subpanel PAH
NX59,Specifieke vraagstelling Exoom
NX60,analyse NGS Preconceptie
NX61,analyse NGS DER; subpanel FH
NX62,Analyse Exoom; NEURO Ataxie volwassenen
NX63,Analyse Exoom; NEURO Spastische paraplegie
NX64,Analyse Exoom; NEURO Dementie
NX65,Analyse Exoom; NEURO Parkinson_parkinsonisme
NX66,Analyse Exoom; NEURO NBIA
NX67,Analyse Exoom; NEURO Ataxie volw en Spastische paraplegie
NX68,Analyse Exoom; kinder DCM
NX69,Analyse Exoom; LEVER cholestase
NX70,Analyse Exoom; Myoclonus volwassen
NX71,Analyse Exoom; Myoclonus kind t/m 17
NX72,analyse exoom; TID
NX73,analyse NGS Preconceptie; PCSp
NX74,Analyse Exoom
NX75,Analyse NGS ONCO; losse genen
NX76,Analyse NGS CARDIO; losse genen
NX77,Analyse NGS ONCO; Borstkanker
NX78,Analyse NGS ONCO; Eierstokkanker
NX79,Analyse NGS ONCO; Darmkanker
NX80,Analyse NGS ONCO; Darmpoliepen
NX81,Analyse NGS ONCO; Maagkanker
NX82,Analyse NGS ONCO; Niet-endocriene alvleesklierkanker
NX83,Analyse NGS ONCO; Endocrinologie-feochromocytomen
NX84,Analyse NGS ONCO; Endocrinologie-NET
NX85,Analyse NGS ONCO; Endocrinologie-(bij)schildklierkanker
NX86,Analyse NGS ONCO; Nierkanker
NX87,Analyse NGS ONCO; Huidkanker
NX88,Analyse NGS ONCO; Kinderonco-meningeoma/schwannoma
NX89,Analyse NGS ONCO; Kinderonco-neuroblastoom
NX90,Analyse NGS ONCO; Kinderonco-medulloblastoom
NX92,Analyse NGS ONCO; Leukemie/Lymfoom
NX93,Analyse NGS ONCO; Prostaatkanker
NX94,Analyse NGS ONCO; Retinoblastoom
NX95,Analyse NGS ONCO; Li Fraumeni syndroom
NX96,Analyse Exoom; NEURO Ataxie Early onset
NX97,Analyse Exoom; NEURO Dandy Walker
NX98,Analyse Exoom; NEURO Joubert like
NX99,Analyse Exoom; NEURO PCH
OAS1,analyse chromosomale Y deleties
OAS3,analyse chromosomale Y deleties -devyser
ONCO1,MLPA analyse MEN1
P1,Mutatie analyse PANK2 gen
P10,Mutatie analyse PLA2G6 gen
P3,MLPA analyse PANK2 / PLA2G6
PAH01,Mutatie analyse EIF2AK4 gen
PGx,farmacogenetisch profiel
QF1,trisomie 13;18;21; XY
QF2,trisomie 13;18;21;XY en uitsluiten maternale bijmenging
QF4,trisomie 13;18;21;XY en uitsluiten MCC na NIPT
R1,Mutatie analyse RB1 gen
R2,MLPA analyse MYCN
R26,MLPA analyse RB1
R28,RB1 promotor hypermethylatie analyse
R3,intragene microsatellieten RB1
RET,Mutatie analyse MECP2 gen
RT10,Mutatie analyse CDKL5 gen
RT12,MLPA analyse MECP2
RT13,Mutatie analyse FOXG1 gen
RT14,Mutatie analyse MEF2C gen
S1,Homozygote deletie analyse SMN1
S12,Mutatie analyse IGHMBP2 gen
S22,MLPA analyse IGHMBP2
S4,MLPA analyse SMN1
S6,Mutatie analyse SMN1 gen
SC1,Mutatie analyse ATXN1 (SCA1) gen
SC2,Mutatie analyse ATXN2 (SCA2) gen
SC3,Mutatie analyse ATXN3 (SCA3) gen
SC4,Mutatie analyse CACNA1A (SCA6) gen
SC5,Mutatie analyse ATXN7 (SCA7) gen
SC9,Mutatie analyse PDYN gen
SCA36,Mutatie analyse NOP56 (SCA36) gen
SH1,Mutatie analyse SHOX1 gen
SMA01,MLPA analyse SMN1 en SMN2
SMA02,MLPA analyse SMN1 en SMN2 PCS
SMS1,Mutatie analyse RAI1 gen
SMS2,MLPA analyse RAI1 17p112 HDAC4 2q37
SNP,SNP array diagnostiek
SNP10,Dragerschap prenataal
SNP11,Dragerschap UPD
SNP12,CNV + LOH detectie CLL
SNP13,CNV + LOH detectie Kahler
SNP14,Translocatie(s)
SNP15,Specifieke vraagstelling array
SNP16,Aanvullende analyse
SNP17,"Prenataal overig "
SNP18,CNV + LOH detectie MDS
SNP2,"CNV detectie "
SNP3,LOH detectie
SNP4,"CNV + LOH detectie "
SNP5,"CNV detectie prenataal "
SNP7,CNV + LOH detectie prenataal
SNP8,UPD detectie
SNP9,Dragerschap CNV
ST3,Mutatie analyse COL2A1 gen
ST4,MLPA analyse COL2A1
ST5,sequentie analyse COL11A1
SVP01,Analyse targeted SVP; KRT5
SVP04,
SVP05,Analyse targeted SVP; AGL
SVP06,Analyse targeted SVP; G6PC
SVP08,Analyse targeted SVP; ED1
SVP14,Analyse targeted SVP; RET
SVP18,
SVP21,Analyse targeted SVP; ASCL1
SVP22,Analyse targeted SVP; L1CAM
SVP26,Analyse targeted SVP; SHOX
SVP27,Analyse targeted SVP; IGHMBP2
SVP28,
SVP29,Analyse targeted SVP; COL2A1
SVP30,Analyse targeted SVP; meerdere losse genen
SVP31,Analyse targeted PCS; CFTR
V01,Cosegregatie-onderzoek VUS
WGS1,whole genome sequencing 5GPM
c29,hoge resolutie array
sh2,MLPA analyse SHOX
